샘플 요청 목록

 카트 문의
시장보고서
상품코드
1797268

세계의 뇌척수염 시장

Encephalomyelitis
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 380 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 뇌척수염 시장은 2030년까지 32억 달러에 도달

2024년에 25억 달러로 추정되는 세계의 뇌척수염 시장은 2024-2030년에 CAGR 4.5%로 성장하며, 2030년에는 32억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 말 뇌척수염은 CAGR 4.6%를 기록하며, 분석 기간 종료시에는 9억 3,170만 달러에 달할 것으로 예측됩니다. 관련 뇌척수염 분야의 성장률은 분석 기간 중 CAGR 5.2%로 추정됩니다.

미국 시장은 6억 7,930만 달러로 추정, 중국은 CAGR 8.2%로 성장 예측

미국의 뇌척수염 시장은 2024년에 6억 7,930만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간2024-2030년 CAGR을 8.2%로, 2030년까지 6억 7,040만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.8%와 3.5%로 예측됩니다. 유럽에서는 독일이 CAGR 2.6%로 성장할 것으로 예측됩니다.

세계의 뇌척수염 시장 - 주요 동향과 촉진요인 정리

뇌척수염은 임상현장에서 어떻게 이해되고 분류되는가?

뇌척수염은 뇌(뇌염)와 척수(척수염)의 동시 염증을 말하며, 대부분 자가면역반응이나 감염에 의해 발생합니다. 급성 파종성 뇌척수염(ADEM), 시신경척수염 스펙트럼 장애(NMOSD), 감염 후 뇌척수염 등 여러 임상 증상을 포함합니다. 바이러스 감염이나 백신 접종 후 발병하기도 하고, 더 광범위한 자가면역질환의 일부로 발병하기도 합니다. 치료 경과와 예후가 크게 달라질 수 있으므로 다른 신경염증성 질환과의 감별이 필수적입니다.

뇌척수염의 복잡성은 시각장애, 운동기능장애, 의식장애, 감각장애 등의 중복된 증상에 있으며, 다발성 경화증이나 감염성 뇌염을 모방할 수 있습니다. 진단을 확정하기 위해 MRI, 뇌척수액 분석, 항체 검사, 특히 NMOSD에서는 아쿠아포린4 항체, MOG 관련 질환에서는 미엘린 올리고덴드로사이트 당단백질(MOG) 항체가 검출됩니다. 인지도 향상과 진단 기준의 정교화로 조기 판별은 개선됐지만, 중복되는 신경염증증후군의 감별은 여전히 과제로 남아있습니다.

진단과 치료의 어떤 발전이 임상 결과를 개선하고 있는가?

신경영상검사와 면역학적 검사의 발전으로 뇌척수염의 진단이 크게 개선되고 있습니다. 고해상도 MRI를 통해 척수 병변이나 뇌의 탈수초 패턴을 조기에 발견할 수 있으며, 유사 질환과의 감별이 가능해졌습니다. AQP4-IgG와 MOG-IgG를 포함한 자가 항체의 면역측정은 보다 정확한 질병 분류를 가능하게 하고 치료 결정의 지침이 되고 있습니다. 조기 진단은 돌이킬 수 없는 신경 손상을 예방하고 장기적인 장애를 줄이는데 매우 중요합니다.

치료법은 원인과 중증도에 따라 다릅니다. 급성기 치료에는 일반적으로 고용량의 코르티코스테로이드 또는 정맥내 면역글로불린(IVIG)을 사용하며, 만성 또는 재발한 경우에는 면역억제제를 사용합니다. 스테로이드 내성, 특히 NMOSD의 경우 혈장 교환이 이루어집니다. 치료 저항성 자가면역질환 환자들을 위해 인터류킨 경로와 보체 단백질을 표적으로 하는 단클론 항체 등 새로운 생물제제들이 등장하고 있습니다. 현재 진행 중인 임상시험에서는 중추신경계의 염증을 억제하고 재수초화를 촉진하는 새로운 치료법을 연구하고 있습니다.

가장 큰 영향을 받는 환자 집단과 의료 시스템은?

뇌척수염은 소아 및 성인 모두에게 영향을 미치지만, ADEM과 같은 특정 아형은 소아에서 더 흔하고, NMOSD와 자가면역성 뇌척수염은 보통 성인에서 더 흔합니다. 의료 시스템에 대한 부담은 급성기 입원 비용뿐만 아니라 장기적인 재활 및 신경학적 치료 비용도 포함됩니다. 질병의 재발, 인지 장애, 운동 장애는 삶의 질을 현저히 떨어뜨리고 장기적인 신경학적 지원 서비스에 대한 의존도를 증가시킬 수 있습니다.

자원이 부족한 환경에서는 오진이나 치료 지연으로 인해 결과가 나빠지는 경우가 많습니다. 신경 영상, 항체 검사, 생물제제에 대한 접근성이 제한되어 있으며, 조기 개입이 제한되고, 그 결과 영구적인 장애가 발생할 확률이 높습니다. 전 세계에서 진단 및 치료 옵션이 개선됨에 따라 접근성 격차가 더욱 두드러지고 있습니다. 희귀질환에 대한 인식 개선 캠페인, 의사 교육, 희귀질환 프로그램 지원은 치료 혜택을 받지 못하는 지역의 진단 및 치료 인프라를 확대하는 데 중요한 역할을 하고 있습니다.

뇌척수염 시장 성장의 원동력은?

뇌척수염 시장 개발은 진단 혁신, 치료법 개발, 질병 인식과 관련된 몇 가지 요인에 의해 촉진되고 있습니다. 자가면역성 신경질환의 유병률 증가와 질병 분류의 개선으로 뇌척수염 아형의 조기 및 정확한 진단이 가능해지고 있습니다. 첨단 영상 검사 및 항체 검사가 가능해짐에 따라 유사 질환과의 임상적 감별이 용이해져 표적화된 치료 접근이 가능해졌습니다.

면역치료제 파이프라인의 확대와 신경염증성 질환에 대한 새로운 모노클로널 항체 도입은 특히 재발성 자가면역성 뇌척수염에 대한 치료 옵션을 넓혀주고 있습니다. 바이오마커와 영상 진단 기술을 포함한 질병 모니터링 툴의 개선으로 치료의 정확성과 결과 추적의 정확성이 향상되고 있습니다. 또한 환자 옹호 활동, 희귀질환에 대한 자금 지원, 교육 보급 활동으로 인지도, 진단율, 케어 서비스에 대한 수요가 증가하고 있습니다. 이러한 요인들이 종합적으로 뇌척수염 진단 서비스, 치료제, 장기 관리 시장의 지속적인 성장을 지원하고 있습니다.

부문

유형(말 뇌척수염, 관련 뇌척수염, AntiMOG, 파종성 뇌척수염, 급성 파종성 뇌척수염, AIDS 관련 뇌척수염, 기타 유형), 치료(외과 치료, Plasmapheresis 치료, 약물 치료, 기타 치료), 최종사용자(클리닉 최종사용자, 병원 최종사용자, 기타 최종사용자)

조사 대상 기업의 예

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech(Roche subsidiary)
  • GlaxoSmithKline plc(GSK)
  • Immunomedics(now part of Gilead Sciences)
  • Janssen Biotech, Inc.(Johnson & Johnson)
  • Merck & Co., Inc.
  • Novartis AG
  • Oncomed Pharmaceuticals
  • Pfizer Inc.
  • Roche(see also Genentech above)
  • Sanofi SA
  • Spectrum Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.09.02

Global Encephalomyelitis Market to Reach US$3.2 Billion by 2030

The global market for Encephalomyelitis estimated at US$2.5 Billion in the year 2024, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Equine Encephalomyelitis, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$931.7 Million by the end of the analysis period. Growth in the Associated Encephalomyelitis segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$679.3 Million While China is Forecast to Grow at 8.2% CAGR

The Encephalomyelitis market in the U.S. is estimated at US$679.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$670.4 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Encephalomyelitis Market - Key Trends & Drivers Summarized

How Is Encephalomyelitis Understood and Classified Across Clinical Contexts?

Encephalomyelitis refers to the simultaneous inflammation of the brain (encephalitis) and spinal cord (myelitis), often triggered by autoimmune responses or infections. It encompasses several clinical conditions, including acute disseminated encephalomyelitis (ADEM), neuromyelitis optica spectrum disorders (NMOSD), and post-infectious encephalomyelitis. In some cases, it follows viral infections or vaccinations, while in others, it presents as part of a broader autoimmune disease. Differentiation from other neuroinflammatory disorders is essential, as treatment pathways and prognosis can vary significantly.

The complexity of encephalomyelitis lies in its overlapping symptoms-such as visual disturbances, motor dysfunction, altered consciousness, and sensory deficits-which may mimic multiple sclerosis or infectious encephalitis. MRI, cerebrospinal fluid analysis, and antibody testing are used to establish diagnosis, particularly to detect aquaporin-4 antibodies in NMOSD or myelin oligodendrocyte glycoprotein (MOG) antibodies in MOG-associated disorders. Increased awareness and refinement in diagnostic criteria have improved early identification, but challenges persist in distinguishing overlapping neuroinflammatory syndromes.

What Advances in Diagnosis and Treatment Are Improving Clinical Outcomes?

Advancements in neuroimaging and immunological testing are significantly improving the diagnosis of encephalomyelitis. High-resolution MRI allows early detection of spinal cord lesions and demyelinating patterns in the brain, supporting differentiation from similar disorders. Immunoassays for autoantibodies, including AQP4-IgG and MOG-IgG, are enabling more accurate disease classification and guiding treatment decisions. Early diagnosis is critical in preventing irreversible neurological damage and reducing long-term disability.

Treatment approaches vary depending on the cause and severity. Acute management typically involves high-dose corticosteroids or intravenous immunoglobulin (IVIG), followed by immunosuppressive agents in chronic or relapsing cases. Plasma exchange is used in steroid-refractory cases, particularly in NMOSD. Newer biologics, such as monoclonal antibodies targeting interleukin pathways or complement proteins, are emerging for patients with treatment-resistant autoimmune encephalomyelitis. Ongoing clinical trials are exploring additional therapies to limit inflammation and promote remyelination in the central nervous system.

Which Patient Populations and Healthcare Systems Are Most Impacted?

Encephalomyelitis affects both pediatric and adult populations, although certain subtypes like ADEM are more common in children, while NMOSD and autoimmune encephalomyelitis are typically seen in adults. The burden on healthcare systems includes not only the cost of acute hospitalization but also long-term rehabilitation and neurological care. Disease relapses, cognitive impairment, and motor disabilities can lead to significant reductions in quality of life and increased dependence on long-term neurological support services.

In low-resource settings, misdiagnosis and delayed treatment often contribute to poorer outcomes. Limited access to neuroimaging, antibody testing, and biologics restricts early intervention, resulting in higher rates of permanent disability. As diagnostic and therapeutic options improve globally, disparities in access are becoming more pronounced. Awareness campaigns, physician training, and funding for rare disease programs are playing a key role in expanding diagnosis and treatment infrastructure in underserved regions.

What Is Driving Growth in the Encephalomyelitis Market?

Growth in the encephalomyelitis market is driven by several factors related to diagnostic innovation, therapeutic development, and disease awareness. Rising incidence of autoimmune neurological disorders and improvements in disease classification are leading to earlier and more accurate diagnosis of encephalomyelitis subtypes. Increasing availability of advanced imaging and antibody testing is facilitating clinical differentiation from similar conditions, supporting targeted treatment approaches.

Expansion of immunotherapy pipelines and introduction of novel monoclonal antibodies for neuroinflammatory diseases are broadening treatment options, particularly for relapsing forms of autoimmune encephalomyelitis. Improved disease monitoring tools, including biomarkers and imaging techniques, are enhancing treatment precision and outcome tracking. Additionally, patient advocacy, rare disease funding, and educational outreach are increasing awareness, diagnosis rates, and demand for care services. These factors are collectively supporting sustained growth in diagnostic services, therapeutics, and long-term management within the encephalomyelitis market.

SCOPE OF STUDY:

The report analyzes the Encephalomyelitis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis, Other Types); Treatment (Surgery Treatment, Plasmapheresis Treatment, Drug Treatment, Other Treatments); End-User (Clinics End-Users, Hospitals End-Users, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech (Roche subsidiary)
  • GlaxoSmithKline plc (GSK)
  • Immunomedics (now part of Gilead Sciences)
  • Janssen Biotech, Inc. (Johnson & Johnson)
  • Merck & Co., Inc.
  • Novartis AG
  • Oncomed Pharmaceuticals
  • Pfizer Inc.
  • Roche (see also Genentech above)
  • Sanofi SA
  • Spectrum Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Encephalomyelitis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Autoimmune Neurological Disorders Drives Clinical Attention Toward Encephalomyelitis Diagnosis and Treatment
    • Increased Recognition of Post-Viral and Parainfectious Triggers Spurs Early Screening for Acute and Subacute Encephalomyelitis
    • Advancements in Neuroimaging and CSF Biomarker Analysis Enhance Accuracy in Differentiating Encephalomyelitis from MS and Other CNS Disorders
    • Growing Awareness of ADEM (Acute Disseminated Encephalomyelitis) in Pediatric and Post-Infectious Populations Fuels Demand for Neurology Referrals
    • Rising Use of Immunomodulatory and Corticosteroid Therapies Strengthens Standard of Care in Inflammatory CNS Conditions
    • Expansion of Autoimmune Encephalitis Research Throws Spotlight on Pathophysiological Overlaps with Encephalomyelitis Syndromes
    • Clinical Trials Exploring Monoclonal Antibody and Biologic Therapies Drive Innovation in Treatment of Severe and Refractory Cases
    • Growth in Neurology Infrastructure Across Emerging Markets Improves Access to Diagnostic and Therapeutic Interventions for CNS Demyelinating Disorders
    • Integration of MRI and Evoked Potential Testing Enhances Neurologist Decision-Making in Complex Encephalomyelitis Presentations
    • Expansion of Biomarker Discovery Research Supports Development of Diagnostic Panels for Autoimmune and Post-Infectious CNS Syndromes
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Encephalomyelitis Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Encephalomyelitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Encephalomyelitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Encephalomyelitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Equine Encephalomyelitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Equine Encephalomyelitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Equine Encephalomyelitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Associated Encephalomyelitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Associated Encephalomyelitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Associated Encephalomyelitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for AntiMOG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for AntiMOG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for AntiMOG by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Encephalomyelitis Disseminata by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Encephalomyelitis Disseminata by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Encephalomyelitis Disseminata by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Acute Disseminated Encephalomyelitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Acute Disseminated Encephalomyelitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Acute Disseminated Encephalomyelitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for AIDS-Related Encephalomyelitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for AIDS-Related Encephalomyelitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for AIDS-Related Encephalomyelitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Drug Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Drug Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Drug Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Plasmapheresis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Plasmapheresis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Plasmapheresis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Clinics End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Clinics End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Clinics End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Hospitals End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Hospitals End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Hospitals End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Encephalomyelitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Encephalomyelitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Encephalomyelitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: China 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: China 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: China 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Encephalomyelitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Encephalomyelitis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Encephalomyelitis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Encephalomyelitis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Encephalomyelitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 95: France Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: France 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: France 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: France 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Encephalomyelitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Germany 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Italy 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Encephalomyelitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 122: UK Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: UK 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Spain 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Spain Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Spain Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Spain 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Russia 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 146: Russia Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Russia Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Russia 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Europe Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Europe 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Encephalomyelitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Encephalomyelitis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Encephalomyelitis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Encephalomyelitis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Encephalomyelitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Australia 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Australia Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Australia Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Australia 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Encephalomyelitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 179: India Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: India 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: India 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 185: India Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: India Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: India 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: South Korea 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: South Korea Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: South Korea Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: South Korea 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Asia-Pacific Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Encephalomyelitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Encephalomyelitis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Encephalomyelitis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Encephalomyelitis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Latin America 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Argentina 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 224: Argentina Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Argentina Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Argentina 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Brazil 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 233: Brazil Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Brazil Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Brazil 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Mexico 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 242: Mexico Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Mexico Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Mexico 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Latin America Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Rest of Latin America 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Encephalomyelitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Encephalomyelitis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Encephalomyelitis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Encephalomyelitis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Middle East 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Iran 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 272: Iran Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Iran Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Iran 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Israel 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 281: Israel Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Israel Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Israel 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Saudi Arabia Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Saudi Arabia 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: UAE 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 299: UAE Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: UAE Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: UAE 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Middle East Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Rest of Middle East 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Encephalomyelitis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Encephalomyelitis by Type - Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Encephalomyelitis by Type - Percentage Breakdown of Value Sales for Equine Encephalomyelitis, Associated Encephalomyelitis, AntiMOG, Encephalomyelitis Disseminata, Acute Disseminated Encephalomyelitis, AIDS-Related Encephalomyelitis and Other Types for the Years 2014, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Encephalomyelitis by Treatment - Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Africa 16-Year Perspective for Encephalomyelitis by Treatment - Percentage Breakdown of Value Sales for Drug Treatment, Other Treatments, Surgery Treatment and Plasmapheresis Treatment for the Years 2014, 2025 & 2030
    • TABLE 317: Africa Recent Past, Current & Future Analysis for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Africa Historic Review for Encephalomyelitis by End-user - Clinics End-Users, Hospitals End-Users and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 319: Africa 16-Year Perspective for Encephalomyelitis by End-user - Percentage Breakdown of Value Sales for Clinics End-Users, Hospitals End-Users and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제